

CURRENT C3G CLINICAL TRIALS

Novartis APPEAR Study

Novartis APPEAR – Key Inclusion Criteria

- Age requirement 18 – 60 years old
- Diagnosis of C3G as confirmed by renal biopsy
- UPCR of at least 1 gram sampled from a first morning void urine collection
- Reduced C3 level
- eGFR above 30
- Participants must be on angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for at least 90 days prior to study start
- Vaccinations to protect against encapsulated bacterial infections

Novartis APPEAR – Key Exclusion Criteria

- No transplants allowed
- More than 50% scarring on Kidney biopsy report
- Liver disease such as Hepatitis B or C virus
- Cardiac disease, pulmonary disease, or Cancer within past 5 years
- History of ECG abnormalities
- The use of immunosuppressants – i.e. cyclophosphamide, prednisone of greater than 7.5mg per day, or corticosteroid

*Study medication – Iptacopan is an oral medication taken twice daily. Study medication must be kept in the refrigerator

CURRENT C3G CLINICAL TRIALS

Apellis/Valiant Study

Apellis/Valiant – Key Inclusion Criteria

- Age requirement (adolescent population 12 -17 years old) Adults 18 and up
- Per biopsy - diagnosis of primary C3G or IC-MPGN (with or without previous renal transplant)
- Weight requirement – must weigh at least 30kg
- Willingness to provide triplicate first morning void urine collections throughout study
- eGFR above 30
- stable meds for 12 weeks prior to randomization
- vaccinations to protect against encapsulated bacterial infections

Apellis/Valiant – Key Exclusion Criteria

- Weight more than 100 kg at screening
- History of meningococcal disease
- Cancer within last 5 years
- Use of rituximab, belimumab, or any investigational anticomplement therapy within 5 half-lives of that product prior to screening
- Any severe recurrent chronic infections
- Known or suspected hereditary fructose intolerance

*Study medication – Pegcetacoplan provided in single-use glass vials. Study drug is administered via subcutaneous (SC). Participants will perform 2 infusions per week